Revital Rattenbach, présidente et fondatrice de 4P-Pharma, a été interviewée par Céline Bosquet dans l’émission “Les Grands Paris de l’Entreprise” qui sera diffusée le lundi 15 mars 2021 à 19h30 sur Demain TV (canal 31 de la TNT) et à 17h sur BSmart TV et sur BSmart.fr.
Revital présentera 4P-Pharma ainsi que nos dernières actualités sur 4P004, notre traitement pour l’arthrose et 4P021, notre solution contre la COVID-19.
Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally.
Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships.
4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis.
The Seal of Excellence is a high-quality label awarded by a panel of international independent experts. 4Moving Biotech project was scored as a high-quality proposal in a highly competitive evaluation process, it recognizes the high value of our breakthrough treatment at EU level.
4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech.
This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens a new therapeutic strategy for these diseases.
“This public-private partnership demonstrates our shared commitment to develop breakthrough and novel therapies that can have a meaningful impact for the millions of patients suffering from dAMD and Stargardt disease worldwide,” says Revital Rattenbach, chairwoman of 4P-Pharma. “Our goal is to accelerate the development of this innovative drug and bring it to the clinic as quickly as possible”.
Valerie Fontaine’s team at IDV From left to right Elodie MONTEIRO, Thinhinane BOUMEDINE, Valérie FONTAINE, Cécile VIDAL
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
4P-Pharma est dans l’émission “Les Grands Paris de l’Entreprise”
Revital Rattenbach, présidente et fondatrice de 4P-Pharma, a été interviewée par Céline Bosquet dans l’émission “Les Grands Paris de l’Entreprise” qui sera diffusée le lundi 15 mars 2021 à 19h30 sur Demain TV (canal 31 de la TNT) et à 17h sur BSmart TV et sur BSmart.fr.
Revital présentera 4P-Pharma ainsi que nos dernières actualités sur 4P004, notre traitement pour l’arthrose et 4P021, notre solution contre la COVID-19.
Pour plus d’information : https://www.bsmart.fr/
4P-Pharma at BIO Europe Spring 2021
Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally.
Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships.
She is looking forward to meet you there!
4Moving Biotech received the Seal of Excellence from the European Commission
4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis.
The Seal of Excellence is a high-quality label awarded by a panel of international independent experts. 4Moving Biotech project was scored as a high-quality proposal in a highly competitive evaluation process, it recognizes the high value of our breakthrough treatment at EU level.
Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases
4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech.
This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens a new therapeutic strategy for these diseases.
Valerie Fontaine’s team at IDV
From left to right Elodie MONTEIRO, Thinhinane BOUMEDINE, Valérie FONTAINE, Cécile VIDAL
Read the full press release :
EN: 20210128_PR_IDV_Lutech_4P_vEN
FR: 20210128_PR_IDV_Lutech_4P_vFR
Press contact Institut de la Vision
Emanuela De Luca, Scientific Communication and Events
E-mail: emanuela.de-luca@institut-vision.org
Press contact SATT Lutech
Jeanne Gaubert, Technology Licensing Officer
E-mail: jeanne.gaubert@sattlutech.com
Press contact 4P-Pharma
Roselina Lam, Business development and Licensing Manager
E-mail: roselina@4p-pharma.com
4P-Pharma at the Biotech Showcase 2021 online
Our chairwoman, Revital Rattenbach, will attend the Biotech Showcase, January 11th – 15th online.
Contact us via the partnering platform or by e-mail to schedule a virtual meeting and discuss collaboration opportunities.
For more information : https://informaconnect.com/biotech-showcase/